Scribe Therapeutics CFO David Parrot reports $ 39,990 common stock acquisition

• Scribe Therapeutics CFO David L. Parrot reported indirect purchases of 2,666 common shares at USD 15 each.
• The shares were attributed to holdings by his spouse and child, at 1,333 shares each.
• Parrot also reported the grant of stock options covering 227,761 shares, including 109,426 performance-based options, with exercise prices of USD 19.13 or USD 15.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scribe Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002127908-26-000004), on July 27, 2026, and is solely responsible for the information contained therein.